For PBI-4050, a combined GPR84 antagonist and FFAR1 agonist, another FFA receptor targeting compound, was investigated for the treatment of IPF, with positive data acquired from an exploratory phase II study [196]. The gene discussed is GPR84; the disease is idiopathic pulmonary fibrosis.